Breaking News

Ori Biotech Expands Cell and Gene Therapy Manufacturing Capabilities

Raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, has secured over $100 million in an oversubscribed Series B funding round. The investment round was led by Novalis LifeSciences with Puhua Capital and Chimera Abu Dhabi coming in as new investors. Existing investors from Ori’s $30 million Series A round in 2020, including Amadeus Capital Partners, Delin Ventures, Northpond Ventures and Octopus Ventures, have continued to support the company with additional fundi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters